Wang Lei-Bo, Zhang Xue-Bin, Liu Jun, Liu Qing-Jun
Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin, China.
Department of Pathology, Tianjin Huanhu Hospital, Tianjin, China.
Front Genet. 2022 Apr 8;13:858882. doi: 10.3389/fgene.2022.858882. eCollection 2022.
: Glioblastoma (GBM) is widely known as a classical kind of malignant tumor originating in the brain with high morbidity and mortality. Targeted therapy has shown great promise in treating glioblastoma, but more promising targets, including effective therapeutic targets, remain to be identified. 18A (KIF18A) is a microtubule-based motor protein that is dysregulated and involved in the progression of multiple human cancers. However, the possible effects of KIF18A on GBM progression are still unclear. : We performed DEG analysis, medical data analysis, and network analysis to identify critical genes affecting glioma progression. We also performed immunohistochemical analysis of the KIF18A levels in 94 patients with glioblastoma and the associated surrounding tissues. Patients were divided into two groups according to the high and low expression. Using a clinical analysis, we showed the potential associations between KIF18A expression and clinical characteristics of 94 GBM patients. We then investigated the effects of KIF18A on GBM cell proliferation by colony establishment, MTT, and immune blogging. The possible effect of KIF18A on GBM tumor growth was determined in mice. : We identified KIF18A as a potential gene affecting GBM progression. We further demonstrated that GBM tissues expressed KIF18A much higher, and its presentation was associated with recurrence in glioblastoma patients. We believe KIF18A promotes GBM cell proliferation. : We demonstrated that KIF18A could be a promising target in treating GBM.
胶质母细胞瘤(GBM)是一种广为人知的起源于大脑的经典恶性肿瘤,发病率和死亡率都很高。靶向治疗在治疗胶质母细胞瘤方面已显示出巨大潜力,但包括有效治疗靶点在内的更有前景的靶点仍有待确定。18A(KIF18A)是一种基于微管的运动蛋白,其表达失调并参与多种人类癌症的进展。然而,KIF18A对GBM进展的可能影响仍不清楚。
我们进行了差异基因分析、医学数据分析和网络分析,以确定影响胶质瘤进展的关键基因。我们还对94例胶质母细胞瘤患者及其相关周围组织中的KIF18A水平进行了免疫组织化学分析。根据表达高低将患者分为两组。通过临床分析,我们展示了KIF18A表达与94例GBM患者临床特征之间的潜在关联。然后,我们通过集落形成、MTT和免疫印迹研究了KIF18A对GBM细胞增殖的影响。在小鼠中确定了KIF18A对GBM肿瘤生长的可能影响。
我们确定KIF18A是影响GBM进展的一个潜在基因。我们进一步证明,GBM组织中KIF18A的表达要高得多,并且其表达与胶质母细胞瘤患者的复发有关。我们认为KIF18A促进GBM细胞增殖。
我们证明KIF18A可能是治疗GBM的一个有前景的靶点。